IM-2-c2 A Lt to Sim A



1613 Prospect Parkway Fort Collins, CO 80525 (t) 970-493-7272 (f) 970-484-9505 www.heska.com

CERTIFIED MAIL LABEL NO. 7099 3400 0017 2890 6827 RETURN RECEIPT REQUESTED

October 13, 2003

Gek-Kee Sim, Ph.D. 543 Franklin Street Denver, CO 80218

RECEIVED

APR 1 9 2004

CFFICE OF PETITIONS

RE:

Patent Applications and Issued Patents covering canine and feline

immunoregulatory molecules

Dear Gek-Kee:

We are currently in the process of reviewing inventorship in several patent families on which you are listed as an inventor. United States patent law requires a patent list as inventors only those who made an inventive contribution to the discovery of the subject matter (e.g., a particular molecule) claimed by that individual patent. Whether or not someone has made an inventive contribution relates to their involvement in the conception of the invention, and determination of such involvement must be made in view of U.S. patent laws covering inventorship. While an initial ("parent") application may be filed listing several inventors, each contributing to a different aspect of the invention, the United States Patent and Trademark Office (USPTO) may rule the application actually claims multiple inventions and will therefore require the parent application be divided into several "divisional" applications, each claiming a single invention (e.g., a single molecule). In such cases, inventorship must follow the claims in each divisional application and therefore requires removal from each application the names of those who did not contribute to the conception of the invention claimed in that individual application.

Two of the recently reviewed patent families relate to canine and feline immunoregulatory molecules. The parent application in each of these families disclosed several immunoregulatory molecules; however, during prosecution of these applications, we were required to select a single molecule (e.g., canine IL-4 proteins) on which to continue prosecution. Molecules that were not chosen at that time will be claimed in subsequently filed divisional applications stemming from the original parent application.

A review of two recently issued U.S. Patents from these families, along with careful consideration of the responses to inquiries sent to each named inventor regarding their involvement, has led to the conclusion that, based on the particular molecules covered by the claims, the named inventors need to be changed. The issued patents to be corrected are:



Exhibit A

Gek-Kee Sim, Ph.D. October 13, 2003 Page 2



U.S Patent No. 6,471,957 B1, issued October 29, 2002, entitled "CANINE IL-4 IMMUNOREGULATORY PROTEINS AND USES THEREOF,"

Listed inventors:

Gek-Kee Sim, Shumin Yang, Matthew J. Dreitz and

. Ramani S. Wonderling

Heska File No. IM-2-C1

Inventorship should be changed to list only Gek-Kee Sim and Matthew J. Dreitz

U.S. Patent 6,482,403 B1, issued November 19, 2002, entitled "CANINE IL-13 IMMUNOREGULATORY PROTEINS AND USES THEREOF,"

Listed inventors: Gek-Kee Sim, Shumin Yang, Matthew J. Dreitz and

Ramani S. Wonderling

Heska File No. IM-2-C2

Inventorship should be changed to list only Shumin Yang

One stipulation for making this change is that we must submit to the USPTO statements from each current named inventor stating that they agree with the changes being made. In order to comply with this requirement, we have included statements to this effect for your review and signature. Please sign the attached documents where indicated and return them to our office as soon as possible. Please keep in mind you may still be listed as an inventor on any currently pending or future divisional applications and you will be listed as an inventor on any issuing patents covering subject matter to which you made an inventive contribution.

If you have any questions regarding this matter, please feel free to contact me at (970) 493-7272 ext. 4174 or Carol Verser at (970) 493-7272 ext. 4116.

Sincerely,

Richard J. Stern, Ph.D.

Patent Agent

Enclosure

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:	Group Art Unit: 1633
Sim, Gee-Kee	Examiner: Kaushal, Sumesh
Yang, Shumin)
Dreitz, Matthew J.	STATEMENT OF AGREEMENT
Wonderling, Ramani S.	REGARDING CHANGE IN
W Oldermis, Raman 5.	INVENTORSHIP
U.S. Patent No.: 6,471,957 B1	Under 37 CFR 1.324(b)(2)
Issue Date: October 29, 2002))
Serial No.: 09/322,409	CERTIFICATE OF MAILING
Filing Date: May 28, 1999	I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450,
Atty. File No.: IM-2-C1	ALEXANDRIA, VIRGINIA 22313-1450, THIS DAY OF 2003.
For: "CANINE IL-4) HESKA CORPORATION
IMMUNOREGULATORY PROTEINS	í _
AND USES THEREOF"	Susan A. Gordon
AND USES THEREOF	
Commissioner for Patents	
P.O. Box 1450 Alexandria, Virginia 22313-1450	
Alexandria, Virginia 22313-1450 Dear Sir:	with the amendments removing Shumin Yang
Alexandria, Virginia 22313-1450 Dear Sir:	
Alexandria, Virginia 22313-1450 Dear Sir: The undersigned hereby states she agrees	ing Gek-Kee Sim and Mathew J. Dreitz as sole

Gek-Kee Sim, Ph.D.



1613 Prospect Parkway Fort Collins, CO 80525 Richard J. Stern, Ph.D. Heska Corporation Intellectual Property Dept. 1613 Prospect Parkway Fort Collins, CO 80525

543 Franklin Street Denver, CO 80218

I also wish to receive the